×

NEMUS Bioscience, Inc. Retains MZ Group as Investor Relations Advisor

COSTA MESA, Calif., March 24, 2015 (GLOBE NEWSWIRE) -- NEMUS Bioscience Inc. (OTCQB: NMUS), a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, announced today it has retained MZ Group as its investor relations advisor.

MZ Group will assist NEMUS Bioscience with building its awareness in the capital markets and communicating its corporate and financial developments to shareholders and investors. Mike Cole, Vice President for MZ North America, and the MZ team will be advising the Company in all facets of corporate and financial communications.

"We selected MZ Group as our investor relations partner after careful review because of the breadth and depth of the consulting they provide," said John Hollister, CEO of NEMUS Bioscience. "We are confident that the team at MZ Group will provide strong support in conveying our business model, growth strategy, competitive advantages, and value proposition to shareholders and the investment community at large. With MZ's ongoing communications support, we continue to focus on developing our line of condition-specific cannabinoids to alleviate symptoms associated with a range of debilitating diseases including Glaucoma, Spasticity associated with Multiple Sclerosis, Anxiety, Epilepsy and anti-infectives, including Methicillin-Resistant Staph Aureus (MRSA)."

"NEMUS Bioscience's product pipeline positions it as a premier developer of cannabis-based pharmaceuticals to address unmet medical needs on a global basis," said Ted Haberfield, President of MZ Group North America. "The Company's partnership with the University of Mississippi for discovery, research and commercialization of cannabis-derived medicines, the only US entity authorized by the Federal government to cultivate cannabis for research, further validates its leading position in this highly regulated market. The Company's market opportunity is immense, with its lead candidate for Glaucoma representing a $1.9 billion market in the U.S. alone and nearly $8 billion world-wide. We look forward to helping the Company with all aspects of its corporate communications and investor relations needs."

About NEMUS Bioscience, Inc.

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabis-based therapeutics for global markets with significant unmet medical needs. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabis-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. The Company is led by a highly qualified team of executives with decades of biopharmaceutical drug development and commercialization experience. For more information, visit www.nemusbioscience.com.

About MZ Group

MZ, founded in 1999, combines capital markets intelligence, global investor targeting, IR technology, corporate governance, media and corporate communication and IR consulting, providing comprehensive programs that successfully build and manage shareholder value. With a team of highly experienced senior professionals and an integrated service portfolio, MZ ensures that companies are provided with the right tools and strategies to interact effectively with the investment community and the media, successfully conveying the investment message. MZ's market intelligence, advisory and tactical support activities for investor relations and corporate communications programs are underpinned by a comprehensive IT infrastructure, allowing companies to rapidly achieve global standards of best practices. For more information, please visit www.mzgroup.us.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995 that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and are based on management's current expectations and assumptions. Such statements involve known and unknown risks, uncertainties and other factors that could cause the Company's actual results to differ materially from the results expressed or implied by such statements. For a discussion of these risks and uncertainties see "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public filings with the Securities and Exchange Commission. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

Contact:
Investor Relations
Mike Cole
MZ Group | Vice President - MZ North America
Main: 949-444-1341
mike.cole@mzgroup.us
www.mzgroup.us

CONTACT: Mike Cole, Main: 949-444-1341 mike.cole@mzgroup.us

Source: Nemus Bioscience